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OBJECTIVE: The objective of this selective EBM review is to determine whether or not fecal 
microbiota transplantation improves symptoms in adults with Irritable Bowel Syndrome. 
STUDY DESIGN: A systematic review of two randomized controlled trials and one case series 
published in English and after 2009. 
DATA SOURCES: All three studies were collected from peer-reviewed journals. Databases 
searched included Cochrane Collaboration and PubMed. 
OUTCOMES MEASURED: Outcomes measured included Bristol Stool Form Scale and IBS 
Severity Scoring System (IBS-SSS). 
RESULTS: Halkjær et al. revealed that the placebo FMT had a significant effect (p=0.008) at 
reducing IBS symptom severity in comparison to the FMT three months after transplantation. 
Johnsen et al. found that, at three months post-FMT, the treatment group showed a statistically 
significant effect (p=0.049) at reducing symptom severity. Mizuno et al. showed that six out of 
the 10 patients achieved a clinical improvement in stool form four weeks following FMT. 
CONCLUSIONS: Out of the three articles reviewed, two found that FMT treatment group 
improved symptoms and one found that the control group given the placebo had a greater effect 
in improving symptoms. 
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INTRODUCTION 
Irritable Bowel Syndrome (IBS) is an idiopathic chronic medical condition that causes 
changes in bowel habits and abdominal pain. It is the most commonly diagnosed gastrointestinal 
condition in the United States with approximately 10-15% of the population living with the 
condition.1 Many suffer for years before seeking out medical care as the symptoms can be vague 
and often are confused with other GI conditions. A specific number of healthcare visits due to 
IBS could not be found, however, only 1 in 4 with IBS seek out medical care for their 
symptoms.2 Even still, IBS consumes a significant amount of health care resources and dollars. 
Of the patients who are referred to gastroenterologist, IBS comprises 40% of the referrals.1 The 
disease also carries a heavy cost burden for patients; this is evident as the direct and indirect 
costs combined total approximately $1.6B each year.3 
IBS is defined as a “chronic functional disorder of the gastrointestinal (GI) tract 
characterized by abdominal pain and altered bowel habits in the absence of an organic disease.”4 
Since it is a functional GI disorder, it is a part of a spectrum of disorders related to how the brain 
and gut interact and function together.5 The exact pathophysiology is not completely understood, 
but potentially includes abnormal motility, visceral hypersensitivity, intestinal inflammation, and 
psychosocial abnormalities.6 There are three subtypes of IBS: constipation-predominant (IBS-C), 
diarrhea-predominant (IBS-D), and mixed (IBS-M), which are determined based on the 
symptomatic presentation. There is no specific diagnostic test for IBS; instead, clinicians use a 
combination of subjective scales to establish this clinical diagnosis, which happens to be a 
diagnosis of exclusion. These scales include the ROME Criteria and Bristol Stool Form Scale. 
The ROME III Diagnostic Criteria requires “recurrent abdominal pain or discomfort… for at 
least three days/month in the last three months, associated with two or more of the following: 
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improvement with defecation, onset associated with a change in the frequency of stool, onset 
associated with a change in the form (appearance) of stool.”7 The Bristol Stool Scale specifically 
focuses on the visual appearance of stool which is then rated on a scale from 1-7 from 
constipation to diarrhea, respectively.  
 Because there is no single underlying etiology to “cure”, traditional treatment methods 
focus on alleviating symptoms. For abdominal pain, SSRIs and probiotics are used. For bloating, 
tricyclic antidepressants, dietary modifications (such as a low FODMAPs diet), and the antibiotic 
rifaximin are options. For constipation, lubiprostone, laxatives, linaclotide, and polyethylene 
glycol are used. For diarrhea, loperamide, eluxadoline, and cholestyramine are used. Because 
IBS is thought to have a psychological component, behavioral therapy such as CBT are often 
recommended to reduce anxiety and depression. Since many patients suffer from various 
symptoms concurrently requiring polypharmacy, it is apparent how burdensome the use of 
multiple medications can be without any promise of a cure. 
 Health care providers, such as physicians and physician assistants, care for IBS patients 
in practically every specialty. It is imperative that they can not only provide symptom relief 
using traditional therapies, but also research up-and-coming treatment options which may 
provide more definitive relief and reduce pill burden. 
 Fecal microbiota transplantation (FMT) is the process of introducing stool from a healthy 
donor into the GI tract of a recipient for therapeutic purposes. The presumed effect of FMT is 
that the healthy gut microbiota will reestablish a homeostatic balance in the patient with impaired 
gut function, thus relieving symptoms. FMT has shown to be effective for C. difficile infections, 
in which a systematic review showed resolution of 92% of cases which had previously failed 
traditional treatment options.8 Correction of altered gut microbiota in those ground-breaking 
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cases have led researchers to view FMT as a potential treatment option for IBS, where altered 
microbiota appears to be hallmark of the disease. Some of the treatment options currently 
available, such as probiotics, antibiotics, and low FODMAP diets, already aim to manipulate the 
gut microbiota with hopes to reestablish homeostatic balance.9 Healthy stool has more than 100 
types of microorganisms10, and the presence of this wide range of microbiota supports the theory 
that FMT may reestablish proper bacterial balance in patients with IBS. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not fecal 
microbiota transplantation improve symptoms in adults with Irritable Bowel Syndrome. 
METHODS 
 Articles were selected for this review by searching for the keywords “Fecal Microbiota 
Transplantation” and “Irritable Bowel Syndrome” in the Cochrane Collaboration and PubMed. 
The articles needed to evaluate Patient-Oriented Evidence that Matters (POEMs). Inclusion 
criteria included studies published after 2009, primary research designs, studies on humans, and 
studies in the English language. Exclusion criteria included studies published before 2009, 
studies not on humans, systematic reviews, and meta-analyses. Table 1 expands upon further 
inclusion and exclusion criteria for each specific study. The statistics analyzed and reported in 
this review include p-values, CER, EER, RBI, ABI, and NNT, with the exception of Mizuno et 
al.9 which solely reports “treatment success.” 
 Two randomized controlled trials and one case series were utilized in this review. The 
populations examined were adults over 18 years old diagnosed with IBS by the ROME III 
Criteria. The intervention in all three studies was FMT. For the control, Mizuno et al.9 used 
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patient baseline, Halkjær et al.10 used placebo capsules, and Johnsen et al.11 used placebo 
colonoscopies. The outcomes measured were improvement in stool form using the Bristol Stool 
Form Scale and improvement in symptom severity using the IBS Severity Scoring System. 
Table 1. Demographics and Characteristics 
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 The outcomes focused on for this selective review were improvement in stool form and 
improvement in symptom severity. The Bristol Stool Form Scale is a diagnostic tool used to 
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describe patient stool consistency in order to examine underlying gut function. The score ranges 
from Type 1, indicating constipation, to Type 7, indicating diarrhea. Types 3 and 4 are 
considered “normal”. The IBS Severity Scoring System (IBS-SSS) transforms the symptoms of 
pain, distension, bowel dysfunction, and quality of life into objective data. The maximum score 
is 500, and a score ≥175 indicates moderate-to-severe disease. These two measurements allow 
for clinical assessment of disease severity. 
RESULTS 
Mizuno et al.9 conducted a case series study examining the efficacy of FMT on 10 
participants aged 25-57 years old who were diagnosed with IBS based on the ROME III criteria. 
The participants had persistent IBS symptoms refractory to traditional medical therapy, and all 
subtypes of IBS were included. The intervention was FMT using a fecal slurry created from 
relative donor’s stool (either spouse, parent, or sibling), which was then administered to the 
participants via colonoscopy. All participants were included in the treatment group and received 
this treatment. There was no control or placebo, instead, the comparison group was patient 
baseline before receiving treatment. Participants were then reevaluated for improvement in stool 
form. Improvement to types 3-4 on the Bristol Stool Form Scale at four weeks post-FMT was 
considered a clinical response. No participants were lost to attrition. No adverse side effects of 
FMT were noted. The researchers found that FMT improved stool form in 6 out of the 10 
participants, making the Treatment Success = 60%. No measure of precision or additional 
statistical analysis was provided in this study.9  
Halkjær et al.10 conducted a double-blinded, randomized controlled study of 52 
participants aged 18-60 years old who were diagnosed with IBS based on ROME III criteria. All 
subtypes of IBS were included. The participants were randomly split 1:1 into either the control or 
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treatment group. The FMT was administered by consuming 25 capsules by mouth daily for 12 
days. The treatment group received capsules which were created using the stool of four donors 
that were combined into one sample. The placebo group received identical appearing capsules 
filled with saline, glycerol, and food coloring. Participants were evaluated for improvement in 
IBS-SSS at three months, with a 50-point reduction in IBS-SSS considered a clinical response. 
One participant dropped out of the study, however, no reasoning for attrition was provided. The 
only side effect of FMT that was more significant in the treatment group versus the placebo 
group was diarrhea. Eight of the 22 patients who received the FMT treatment capsules showed a 
reduction in IBS symptoms at three months post-FMT; 19 of the 24 patients who received the 
placebo capsules showed a reduction (p=0.008). The NNT was -2 (Table 2). Therefore, the 
placebo group had a significantly greater reduction in IBS symptom severity in comparison to 
the treatment group (p=0.008).10 
Table 2. Treatment Effect of FMT Using IBS-SSS at Inclusion and 3-month Visit 
 CER EER RBI ABI NNT 
Halkjær et al.10 0.792 0.364 -0.54 -0.428 -2 
CER: Control Event Rate     EER: Experimental Event Rate     RBI: Relative Benefit Increase     ABI: Absolute Benefit Increase     NNT: Numbers Needed to Treat 
Johnsen et al.11 conducted a double-blinded, randomized controlled trial of 90 
participants aged 33-56 years old who were diagnosed with IBS based on the ROME III criteria. 
Participants were split into the treatment group versus placebo group using a 2:1 ratio. The 
treatment group received FMT via colonoscopy delivery of the donor stool of two donors. The 
control group received a placebo FMT via colonoscopy delivery of the participant’s own stool. 
Participants were evaluated for symptom improvement at three and 12 months post-FMT, where 
a 75-point reduction in the IBS-SSS was considered a clinical response. Four participants were 
excluded from the trial because they developed colitis post-FMT which could have 
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inappropriately impacted the results, and three participants did not show up for the FMT with no 
additional reasoning provided. This left 83 participants for analysis. One participant experienced 
an adverse side effect of FMT (vertigo and nausea). 36 of the 55 participants who received the 
FMT treatment showed reduction in IBS symptoms at three months post-FMT, whereas only 12 
of the 28 patients who received the placebo capsules showed reduction (p=0.049). The NNT was 
5 (Table 3). Overall, this showed that the active FMT treatment had a precise and statistically 
significant effect in improving symptoms in patients with IBS. 
Table 3. Treatment Effect of FMT Using IBS-SSS at Inclusion and 3-month Visit 
 CER EER RBI ABI NNT 
Johnsen et al.11 0.43 0.65 0.51 0.22 5 
CER: Control Event Rate     EER: Experimental Event Rate     RBI: Relative Benefit Increase     ABI: Absolute Benefit Increase     NNT: Numbers Needed to Treat 
DISCUSSION 
 Altered gut microbiota is a speculated cause of IBS, but only recently has FMT been 
speculated as a potential cure for IBS. This systematic review analyzed how FMT might alleviate 
symptom severity in individuals suffering from IBS. Two of the studies, Mizuno et al.9 and 
Johnsen et al.11, found FMT to be efficacious in reducing IBS symptoms, and one of the studies, 
Halkjær et al.10, found the placebo to be more effective than the FMT treatment.  
Mizuno et al.9 results showed that FMT was successful in reducing symptoms as six out 
of the 10 patients achieved a clinical response in stool form four weeks post-FMT. However, the 
clinical significance of the study is limited as it does not have a control group to compare 
treatment effectiveness. The duration of the study was shorter than the other two studies as the 
main end point was four weeks post-FMT. Also, the study was not blinded so all participants 
knew they were receiving active treatment which may have led to a false perception of symptom 
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improvement. Additionally, the generalizability is limited due to the small population size of 
only 10 participants, and the study was conducted in Japan. Mizuno et al.9 was the only study in 
this analysis to use donor stool from relatives specific to the individual participants, instead of a 
combination of donor stool unrelated to the participant. This allows for more variables as the 
individuals are technically receiving different stool samples. Overall, given the promising results 
of this study, it would be beneficial for the authors of this study or additional researchers to 
proceed with similar treatment parameters but in a RCT design instead of a case series, which 
would strengthen the results by improving the aforementioned limitations. 
Halkjær et al.10 found that the placebo FMT significantly (p=0.008) reduced symptoms 
versus active FMT. Both this study and Johnsen et al.11 followed participants for the same 
duration, as the primary end points were both three months. Generalizability is limited as the 
study was conducted in Denmark. Also, of note, this study did not screen stool for pathogens 
prior to FMT, whereas the other two studies did. This may have reduced efficacy and even 
caused adverse reactions to both the treatment and control groups. Another factor that may have 
affected the study is the method of administration, as this study used capsules taken by mouth 
while the other two used colonoscopies.  It would be crucial to determine if this impacted the 
perceived treatment effect for the participants, so that moving forward the most efficacious 
delivery system can be utilized in future studies of FMT. 
Johnsen et al.11 found that FMT was effective at reducing symptoms versus the placebo 
treatment (p=0.049). However, total retention time of the FMT inside the bowel was not 
recorded, which potentially could influence how successful the FMT uptake was. Another 
variable was fresh versus frozen FMT. The researchers used a combination of storage techniques 
including directly transferring fresh stool as well as preserving frozen stool before transfer at a 
Buskirk, FMT and IBS  |  9 
 
later date. They did not record these assignments so did not conduct analysis about whether one 
method was more effective than the other. Also, generalizability was limited because only IBS 
subtypes IBS-M and IBS-D were included, therefore, the effect on IBS-C cannot be inferred.  
General research regarding the safety of FMT has been gathered during studies 
examining the efficacy of FMT for C. difficile infections. However, the risks and safety of the 
procedure are similarly applicable as the mechanism of transplantation is the same. The most 
common severe risk associated with FMT is transmission of infectious diseases from the donor 
stool into the digestive tract of the recipient; to reduce this risk, the FDA recommends proper 
screening and testing of donor stool prior to transplantation.12 As previously mentioned, Mizuno 
et al.9 and Johnsen et al.11 both screened for pathogens, whereas Halkjær et al.10 did not. 
Nonetheless, none of the studies in this review had any reported side effects directly attributed to 
an infectious etiology as a result of the FMT. 
 Additionally, FMT is considered “experimental” for IBS and is not covered by most 
insurances, thus making it a challenge to currently study and implement FMT as a treatment 
option. However, FMT is now considered an indication for C. difficile infections after numerous 
studies have analyzed its efficacy and proved it a successful treatment.13,14 Researchers are 
hopeful that as more studies analyze the promising effects of FMT for IBS, insurances will begin 
to cover it. This will make it accessible for all patients instead of solely those who can afford it, 
and promote the use by health care providers who will be sufficiently reimbursed for the 
procedure. Therefore, it is pertinent that physicians and advanced practice providers such as 
physician assistants stay informed on further research regarding FMT as a possible treatment 
option for IBS and other GI disorders. 
CONCLUSION 
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 Of the three studies analyzed, one RCT and one case study found that FMT was 
successful in reducing symptoms, whereas the second RCT found the placebo to reduce 
symptoms more than FMT. Therefore, the results of this systematic review are inconclusive as 
the evidence is conflicting. However, given the promising results of two of the studies, FMT 
appears to have potential to be an effective treatment for IBS and warrants further exploration. 
Future studies should aim to analyze the significance of the source of donor stool, either single-
donor or multi-donor, and mechanism of transplantation, either oral capsules or colonoscopy. 
Researchers should closely monitor stool retention time post-transplantation, subtype of IBS the 
participants are diagnosed with, screening of stool to eliminate risk of infection transmission, and 
whether fresh or frozen stool is used. While the pathophysiology of IBS is still unknown, studies 
examining FMT as a treatment option have the ability to provide symptomatic relief while 
simultaneously learning about the potential etiology.
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